This indicates that antibody responses against the HIV-1 Env, potentially reducing the HIV-1 infection risk that were induced by the initial prime-boost schedule, can be boosted and maintained by repeated injections with a single dose of MVA-CMDR. Here, GJA1 is linked to HIV-1 infection.